Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Caristo Diagnostics’ CaRi‑Heart® technology has demonstrated strong clinical adoption across the UK and EU, with more than double year-over-year growth in clinical use as of mid‑2024. The platform provides novel imaging biomarkers for coronary inflammation and plaque burden from routine cardiac CT scans, improving early detection of cardiovascular disease. It has been validated through partnerships with major hospitals and used as a core lab in multi-country phase II trials for pharmaceutical partners. The company’s technology underpinned a successful phase IIa trial monitoring the anti-inflammatory drug Orticumab from Abcentra, presented at ACC24.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Caristo Diagnostics.